Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 25Lymphoma, Large B-Cell, Diffuse 16Lymphoma 15Burkitt Lymphoma 11Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Follicular 7Lymphoma, B-Cell 7Hodgkin Disease 6Lymphoma, Non-Hodgkin 5Recurrence 3Prostatic Neoplasms, Castration-Resistant 3Leukemia 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Multiple Myeloma 2Melanoma 2Lymphoproliferative Disorders 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, AIDS-Related 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, Biphenotypic, Acute 2Immunoblastic Lymphadenopathy 2Vasculitis, Central Nervous System 1Urogenital Neoplasms 1Stiff-Person Syndrome 1Stage II Prostate Adenocarcinoma 1Skin Neoplasms 1Rasmussen subacute encephalitis 1Prostate Cancer, Hereditary, 7 1

Interventions

prednylidene 1deltacortene 1apalutamide 1Prednisone 1Gonadotropin-Releasing Hormone 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Stage II Prostate Adenocarcinoma × Prednisone × Clear all
NCT02949284 2026-01-07

Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

Rutgers, The State University of New Jersey

Phase 2 Active not recruiting
90 enrolled
Genitourinary

Stage II Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡